FDA accepts Rezzayo supplemental NDA for priority review

CorMedix said the FDA accepted and granted Priority Review to the sNDA for REZZAYO for prophylaxis of invasive fungal disease, with a PDUFA target action date in Q1 2027.Material DetailsContext by AI AnalystThis is a mid-cycle regulatory step advancing REZZAYO from treatment-only use toward a proph…